| Catalog No. | HC440016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Surface-expressed protease, Gelatine degradation protease FAP, Integral membrane serine protease, Dipeptidyl peptidase FAP, Seprase, FAP, Post-proline cleaving enzyme, APCE, SIMP, FAPalpha, 170 kDa melanoma membrane-bound gelatinase, Fibroblast activation protein alpha, Serine integral membrane protease, Prolyl endopeptidase FAP |
|---|
| Concentration | 2.8mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q12884 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -419°C. |
|---|
| Alternate Names | BIBH1,CAS:216669-97-5 |
|---|
| Background | Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC). |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
